Hasil Pencarian - Catherine Sebban

  • Menampilkan 1 - 4 hasil dari 4
Perbaiki Hasil
  1. 1
    Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group

    Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study gr... oleh David Sibon, Franck Morschhauser, Matthieu Resche-Rigon, David Ghez, Jehan Dupuis, Ambroise Marçais, Bénédicte Deau-Fischer, Reda Bouabdallah, Catherine Sebban, Gilles Salles, Pauline Brice

    Diterbitkan 2016-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial

    Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Stud... oleh Nicolas Mounier, Taoufik El Gnaoui, Hervé Tilly, Danièle Canioni, Catherine Sebban, René-Olivier Casasnovas, Richard Delarue, Anne Sonet, Pauline Beaussart, Tony Petrella, Sylvie Castaigne, Serge Bologna, Gilles Salles, Alain Rahmouni, Philippe Gaulard, Corinne Haioun

    Diterbitkan 2013-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma

    Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma oleh Emmanuel Bachy, Roch Houot, Franck Morschhauser, Anne Sonet, Pauline Brice, Karim Belhadj, Guillaume Cartron, Bruno Audhuy, Christophe Fermé, Pierre Feugier, Catherine Sebban, Vincent Delwail, Hervé Maisonneuve, Steven Le Gouill, Sophie Lefort, Nicole Brousse, Charles Foussard, Gilles Salles

    Diterbitkan 2013-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients

    Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients oleh Marie-Lorraine Chretien, Benjamin Hebraud, Valérie Cances-Lauwers, Cyrille Hulin, Gerald Marit, Xavier Leleu, Lionel Karlin, Murielle Roussel, Anne-Marie Stoppa, Francois Guilhot, Thierry Lamy, Laurent Garderet, Brigitte Pegourie, Mamoun Dib, Catherine Sebban, Pascal Lenain, Sabine Brechignac, Bruno Royer, Marc Wetterwald, Laurence Legros, Frédérique Orsini-Piocelle, Laurent Voillat, Xavier Delbrel, Denis Caillot, Margaret Macro, Thierry Facon, Michel Attal, Philippe Moreau, Hervé Avet-Loiseau, Jill Corre

    Diterbitkan 2014-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: